

Correction

Correction: Neamatallah et al. Nano Ellagic Acid Counteracts Cisplatin-Induced Upregulation in OAT1 and OAT3: A Possible Nephroprotection Mechanism. *Molecules* 2020, 25, 3031

Thikryat Neamatallah ¹, Nagla El-Shitany ^{1,2,*}, Aymn Abbas ^{3,4}, Basma G. Eid ¹, Steve Harakeh ^{3,5}, Soad Ali ⁶ and Shaker Mousa ⁵

¹ Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia

² Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta 31511, Egypt

³ Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia

⁴ Biotechnology Research Laboratories, Gastroenterology Surgery Center, Mansoura University, Mansoura 35511, Egypt

⁵ Yousef Abdullatif Jameel Chair of Prophetic Medicine Application, King Abdulaziz University, Jeddah 21589, Saudi Arabia

⁶ Anatomy Department of Cytology and Histology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia

* Correspondence: nagla_fouad@yahoo.com or nalshitany@kau.edu.sa

Error in Figure

In the original publication, there was a mistake in Figure 3 as published [1]. We observed that photo B was mistakenly presented in the cisplatin group. However, this photo was from the ellagic acid nano (2 mg/kg) group. So, we changed photo B with another photo from the cisplatin group. This doesn't change the conclusion made. The corrected Figure 3 appears below.



Citation: Neamatallah, T.; El-Shitany, N.; Abbas, A.; Eid, B.G.; Harakeh, S.; Ali, S.; Mousa, S. Correction: Neamatallah et al. Nano Ellagic Acid Counteracts Cisplatin-Induced Upregulation in OAT1 and OAT3: A Possible Nephroprotection Mechanism. *Molecules* 2020, 25, 3031. *Molecules* **2023**, *28*, 5626. <https://doi.org/10.3390/molecules28155626>

Received: 12 November 2022

Accepted: 29 January 2023

Published: 25 July 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).




Figure 3. Cont.




Figure 3. Impact of ellagic acid nanoformulation on kidney OAT3 immunoexpression examined in cisplatin-treated rats. (A): Control group; (B): Cisplatin group; (C): Ellagic acid nano (1 mg/kg); and (D): Ellagic acid nano (2 mg/kg). (E): Bar chart showing OAT3 immunoexpression (area %) in the different experimental groups. Results are given as mean $\pm$ SE (n = 6). * $p \leq 0.05$ relative to the control group; # $p \leq 0.05$ relative to cisplatin group; Ω $p \leq 0.05$ relative to ellagic acid nano (1 mg/kg) group.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

1. Neamatallah, T.; El-Shitany, N.; Abbas, A.; Eid, B.G.; Harakeh, S.; Ali, S.; Mousa, S. Nano ellagic acid counteracts cisplatin-induced upregulation in OAT1 and OAT3: A possible nephroprotection mechanism. *Molecules* **2020**, *25*, 3031. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.